For the year ending 2025-12-31, CARL had $45,668K increase in cash & cash equivalents over the period. -$29,619K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -29,634 |
| Depreciation and amortization | 281 |
| Stock-based compensation | 1,927 |
| Non-cash interest | 206 |
| Loss on remeasurement of warrant liabilities | 328 |
| Non-cash lease expense | 536 |
| Provision for credit losses | 414 |
| Provision for excess and obsolete inventory | 1,839 |
| Other non-cash items | -17 |
| Accounts receivable, net | 5,010 |
| Inventory | 2,689 |
| Prepaid expenses and other assets | 2,342 |
| Accounts payable | 2,323 |
| Accrued liabilities | 627 |
| Accrued compensation | 2,490 |
| Lease liabilities | -290 |
| Net cash used in operating activities | -28,977 |
| Purchase of short-term investments | 24,000 |
| Purchase of property and equipment | 642 |
| Capitalized software costs | 715 |
| Payment of initial direct costs related to operating leases | 126 |
| Net cash used in investing activities | -25,483 |
| Proceeds from initial public offering, net of underwriting discounts and commissions | 93,465 |
| Payments for deferred initial public offering costs | 5,411 |
| Proceeds from issuance of series c convertible preferred stock, net of issuance costs | 11,919 |
| Proceeds from term loan, net of issuance costs | 0 |
| Payment of issuance costs related to term loan modification | 50 |
| Proceeds from exercises of stock options | 205 |
| Net cash provided by financing activities | 100,128 |
| Increase in cash, cash equivalents, and restricted cash | 45,668 |
| Cash, cash equivalents, and restricted cash at beginning of the period | 40,225 |
| Cash, cash equivalents, and restricted cash at end of the period | 85,893 |
CARLSMED, INC. (CARL)
CARLSMED, INC. (CARL)